J Rheum Dis 2017; 24(2): 114-118
Published online April 30, 2017
© Korean College of Rheumatology
Correspondence to : Chang-Hee Suh, Department of Rheumatology, Ajou University School of Medicine, 164 WorldCup-ro, Yeongtong-gu, Suwon 16499, Korea. E-mail:chsuh@aumc.ac.kr
This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pulmonary arterial hypertension is a critical manifestation of systemic sclerosis (SSc) and is a main cause of death. Several treatment modalities for SSc have been identified, with effects that improve quality of life and mortality rates. However, whether these drugs can also normalize pulmonary arterial pressure, remains unclear. Here, we report the case of a woman with diffuse SSc with pulmonary arterial hypertension, who had a functional status equivalent to the New York Heart Association class III. The patient was treated with inhaled iloprost. After six years of inhaled iloprost therapy, echocardiography showed that pulmonary arterial pressure normalized, accompanied by improvement in functional capacity. Inhaled iloprost might not only normalize pulmonary arterial pressure, but also improve the functional status of patients with SSc with pulmonary arterial hypertension.
Keywords Systemic sclerosis, Pulmonary hypertension, Iloprost
J Rheum Dis 2017; 24(2): 114-118
Published online April 30, 2017 https://doi.org/10.4078/jrd.2017.24.2.114
Copyright © Korean College of Rheumatology.
So-Young Yoon, Eun-Soo Yoo, Eun-Jung Yoo, Ju-Yang Jung, Hyoun-Ah Kim, Chang-Hee Suh
Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea
Correspondence to:Chang-Hee Suh, Department of Rheumatology, Ajou University School of Medicine, 164 WorldCup-ro, Yeongtong-gu, Suwon 16499, Korea. E-mail:chsuh@aumc.ac.kr
This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pulmonary arterial hypertension is a critical manifestation of systemic sclerosis (SSc) and is a main cause of death. Several treatment modalities for SSc have been identified, with effects that improve quality of life and mortality rates. However, whether these drugs can also normalize pulmonary arterial pressure, remains unclear. Here, we report the case of a woman with diffuse SSc with pulmonary arterial hypertension, who had a functional status equivalent to the New York Heart Association class III. The patient was treated with inhaled iloprost. After six years of inhaled iloprost therapy, echocardiography showed that pulmonary arterial pressure normalized, accompanied by improvement in functional capacity. Inhaled iloprost might not only normalize pulmonary arterial pressure, but also improve the functional status of patients with SSc with pulmonary arterial hypertension.
Keywords: Systemic sclerosis, Pulmonary hypertension, Iloprost
Sang Yeob Lee, Sang Woo Yim, Jun Yong Park, Won Tae Chung, Sung Won Lee
J Rheum Dis 2015; 22(1): 19-24Bong-Woo Lee, M.D., Eui-Jong Kwon, M.D., Ji Hyeon Ju, M.D., Ph.D.
J Rheum Dis -0001; ():Ha-Hee Son, M.D., Su-Jin Moon, M.D., Ph.D.
J Rheum Dis -0001; ():